A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis
K. Tong (Newcastle, NSW, Australia), D. Dorahy (Newcastle, NSW, Australia), M. France (Brisbane, QLD, Australia), L. Burr (Brisbane, QLD, Australia), H. Greville (Adelaide, SA, Australia), S. Visser (Sydney, NSW, Australia), P. Middleton (Sydney, NSW, Australia), C. Wainwright (Brisbane, QLD, Australia), D. Barker (Newcastle, NSW, Australia), P. Wark (Newcastle, NSW, Australia)
Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis
Session: Advances in care and monitoring of cystic fibrosis
Session type: Oral Presentation
Number: 2126
Disease area: Paediatric lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Tong (Newcastle, NSW, Australia), D. Dorahy (Newcastle, NSW, Australia), M. France (Brisbane, QLD, Australia), L. Burr (Brisbane, QLD, Australia), H. Greville (Adelaide, SA, Australia), S. Visser (Sydney, NSW, Australia), P. Middleton (Sydney, NSW, Australia), C. Wainwright (Brisbane, QLD, Australia), D. Barker (Newcastle, NSW, Australia), P. Wark (Newcastle, NSW, Australia). A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis. 2126
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study Source: ERJ Open Res, 6 (1) 00172-2019; 10.1183/23120541.00172-2019 Year: 2020
The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study Source: Eur Respir J, 53 (3) 1801587; 10.1183/13993003.01587-2018 Year: 2019
Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study Source: ERJ Open Res, 5 (1) 00175-2018; 10.1183/23120541.00175-2018 Year: 2019
Multi-institutional prospective cohort study of prognostic factors in patients with idiopathic pulmonary fibrosis receiving long-term oxygen therapy. Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019
The prevalence and diversity of fungi in respiratory samples of cystic fibrosis patients – a Dutch, nationwide, prospective, multicentre study Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018
A real life multicenter national study on the use of nintedanib in moderate to severe IPF patients Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017
PEGASUS - the effects of commercial air travel on patients suffering from pulmonary hypertension - a prospective, multicenter, multinational study Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018
Prospective observational study in patients with obstructive lung disease: NOVELTY design Source: ERJ Open Res, 5 (1) 00036-2018; 10.1183/23120541.00036-2018 Year: 2019
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study Source: ERJ Open Res, 8 (1) 00443-2021; 10.1183/23120541.00443-2021 Year: 2022
A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Aspergillus pulmonary disease in cystic fibrosis (CF) patients: multicentre perspective observational study based on new diagnostic tests to evaluate the prognostic value on the CF disease Source: Virtual Congress 2021 – Adult cystic fibrosis Year: 2021
A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol Source: ERJ Open Res, 5 (4) 00186-2019; 10.1183/23120541.00186-2019 Year: 2019
The effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis- A randomised controlled trial Source: International Congress 2017 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2017
Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis. Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019
A multicentre cohort study on the association between common markers of asthma and the incidence of COPD Source: Eur Respir J 2006; 28: Suppl. 50, 295s Year: 2006
A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007
1-year prospective study in severe COPD patients: marker of inflammation, lung function and radiologic evaluation Source: Annual Congress 2007 - Pathophysiology and assessment of COPD Year: 2007
The evaluation of the efficacy and safety of phospholipids‘ inhalation in patients with bronchial asthma (BA): A prospective randomized placebo-controlled study Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016